Switching from GLP-1 Injections to Wegovy Pill Shows Additional Weight Loss of 4.1%

Recent research shows people who switch to the Wegovy pill from a GLP-1 injection can lose additional weight. PixelsEffect · E+/Getty People with overweight or obesity who switched from an injectable GLP-1 weight loss medication to the Wegovy (semaglutide) pill lost an average of 4.1% of their body weight over 3 months. After 3 months, about 2 in 5 participants had lost at least 5% of their body weight. The proportion of participants with obesity decreased by 21.6 percentage points, from 87.1% at the start of the study to 65.5% after 3 months. People with overweight or obesity who switch from an injectable GLP-1 medication to the Wegovy (semaglutide) pill may continue to lose weight, according to findings from the OCTANE study presented at the 2026 Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. The study is among the first real-world analyses to examine weight loss and treatment experiences among people who switched from an injectable weight loss medication to oral semaglutide (Wegovy). However, while real-world studies like this can provide useful insights into how treatments work in everyday life, these findings do not prove that switching …

≈